Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overacti... (

HOME >> MEDICINE >> TECHNOLOGY

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder

Date:5/21/2008

- Innovative pipeline products highlight Watson's commitment to urology -

Embargoed Until 2:10 PM EDT

ORLANDO, Fla., May 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that investigators presented clinical data on two Phase 3 products at the American Urological Association's annual meeting. The abstracts include a cardiac safety trial involving silodosin, an investigational treatment for benign prostatic hyperplasia (BPH, or prostate enlargement) and a pharmacokinetic study of oxybutynin chloride topical gel (OTG), an investigational product for overactive bladder.

"Watson is committed to helping urologists offer their patients the highest standard of care through providing novel treatments that continually address areas of urology with limited therapeutic options," said Edward Heimers, Jr., Executive Vice President and President of Watson's Brand Division. "We are extremely encouraged by the results demonstrated in these two trials, as they support the safety of silodosin and the potential efficacy of OTG as well as offer important patient benefits. A marketing application for silodosin has been filed with the FDA, and one for OTG will be filed. Both products represent potentially important additions to the expanding Watson urology franchise."

In the first trial (abstract #2037), investigators conducted a double-blind, randomized, parallel-group trial to assess whether or not silodosin -- an investigational alpha blocker -- would prolong the QT interval on an electrocardiogram (ECG). QT is a measure of the heart's electrical activity. A prolongation of the QTc (corrected for heart rate) interval favors the develo
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Launches Generic Biaxin(R) XL
4. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
5. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
6. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
7. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
8. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
9. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
10. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
11. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer

Post Your Comments:

(Date:5/17/2013)... , May 17, 2013 Boehringer Ingelheim will ... disease at the American Thoracic Society International Conference ... , May 17 – 22. Data ... for the treatment of chronic obstructive pulmonary disease ... well as investigational compounds for asthma, idiopathic pulmonary ...

(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013. ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...

(Date:5/16/2013)... Nektar Therapeutics, (Nasdaq: NKTR ) President and ... is scheduled to present at the upcoming 2013 UBS Global ... the Sheraton New York Hotel on Tuesday, May 21, 2013 ... be accessible via a Webcast through a link posted in ... http://www.nektar.com . This Webcast will be available for replay ...

Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7 Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8 Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2 Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2

[0] Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference [0] Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results [0] Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City

... , , OXFORD, England ... specialty,pharmaceutical company focused on the needle-free administration of solid,dose ... an,oversubscribed GBP2.7 million ( $4.3 million ) ... existing institutional and private,investors, including Hygea VCT and Oxford ...

... , NEW YORK and TOKYO ... that it has acquired iCyt Mission Technology, Inc. (iCyt), a leading ... research, through its U.S. subsidiary, Sony Corporation of America (SCA). With ... the flow cytometry business in the life science field. iCyt, founded ...

Cached Medicine Technology:Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round 2 Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round 3 Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 2 Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 3

Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt

(Date:5/18/2013)... few extra cups of coffee each month might help ... as primary sclerosing cholangitis (PSC), a new study suggests. ... found that drinking coffee was associated with a reduced ... cirrhosis of the liver, liver failure and biliary cancer. ... "While rare, PSC has extremely detrimental effects," ...

(Date:5/18/2013)... Orlando, FL (May 18, 2013) There are ... procedures commonly used to diagnose or treat gastrointestinal ... Week (DDW). , A study by New ... that more objective testing may substantially reduce the ... (GERD). Although GERD is believed to affect nearly ...

(Date:5/18/2013)... Assisted living and retirement communities have ... comfort of their residents. Systems Technologies is well-acquainted ... effective and cost-efficient solution – VisionLink Wireless Nurse ... communications solution that helps nurses provide the highest ... privacy. , The VisionLink nurse call ...

(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... pelvic mesh products continue to move forward in a ... Court, Bernstein Liebhard LLP reports. According to a notice ... in the Ethicon pelvic mesh litigation will be held ... 2,755 complaints have been filed in the proceeding on ...

(Date:5/18/2013)... 2013 The “World Healthcare IT Market: ... the major market drivers, restraints, and opportunities in North ... Browse , 89 market data ... on "Healthcare IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html ... reports. , The global healthcare IT market is expected ...

Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2 Health News:New research identifies practice changes to improve value and quality of GI procedures 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3 Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2 Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3 Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2 Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3

[0] Study Links Coffee to Lower Risk for Rare Liver Disease [0] New research identifies practice changes to improve value and quality of GI procedures [0] VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities [0] Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation [0] Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets

... of phosphate in the blood are more likely to ... key indicator of atherosclerosis and future cardiovascular disease risk, ... the Journal of the American Society of Nephrology ... unidentified and modifiable cardiovascular risk factor, and could help ...

... Diluted Share, FARMINGDALE, N.Y., Nov. 13 Misonix, ... ultrasonic medical device,technology, which in Europe is used for ... conditions, today reported financial,results for its fiscal year 2009 ... President and Chief Executive Officer, and Richard,Zaremba, Senior VP ...

... Savings Over 70% Are Easily Found with Free, ... 13 With one-quarter of,Americans paying out-of-pocket to ... in coming months, PharmacyChecker.com published "Safe,Strategies for Drug ... By,shopping online at verified pharmacies in the U.S., ...

... S.C., Nov. 13 Companion Benefit,Alternatives Inc. ... and substance,abuse treatment benefits in South Carolina, ... among 23 finalists in URAC,s prestigious,Best Practices ... Awards,competition., URAC, a leading independent accrediting ...

... more stringent standards that require nurses to submit fingerprints and undergo ... years. RecordGone.com helps nurses expunge their criminal records, making it ... , ... Costa Mesa, CA (PRWEB) November 13, 2008 ...

... gender, race and/or marital status can factor into the ... gender is the most significant factor impacting overall survival, ... Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, ... National Cancer Institute, in 2008 approximately 215,020 new cases ...

High-normal phosphate levels linked to early atherosclerosis Misonix Reports First Quarter Fiscal Year 2009 Financial Results PharmacyChecker.com Publishes 'Safe Strategies for Drug Savings' to Help All Americans Get Affordable Medication CBA's Innovative Program for Managing Depression Earns National Recognition RecordGone.com Helps California Nurses Expunge Criminal Records to Meet More Stringent Licensing Standards Gender is key factor in determining overall survival of lung cancer patients

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Allergen, Occupational, Phthalic Anhydride Allergen, Occupational, Isocyanate TDI Allergen, Occupational, Ethylene Oxide Allergen, Mites, Euroglyphus maynei